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Abstract. 
 
Phosphatidylinositol 3-kinase (PI 3-kinase) is 
a lipid kinase which has been implicated in mitogenesis, 
protein trafﬁcking, inhibition of apoptosis, and integrin 
and actin functions. Here we show using a green ﬂuo-
rescent protein–tagged p85 subunit that phosphatidylino-
sitol 3-kinase is distributed throughout the cytoplasm 
and is localized to focal adhesion complexes in resting 
NIH-3T3, A431, and MCF-7 cells. Ligand stimulation of 
an epidermal growth factor receptor/c-erbB-3 chimera 
expressed in these cells results in a redistribution of p85 
to the cell membrane which is independent of the cata-
lytic activity of the enzyme and the integrity of the actin 
cytoskeleton. The movement is, however, dependent on 
the phosphorylation status of the erbB-3 chimera. Us-
ing rhodamine-labeled epidermal growth factor we 
show that the phosphatidylinositol 3-kinase and the re-
ceptors colocalize in discrete patches on the cell sur-
face. Low concentrations of ligand cause patching only 
at the periphery of the cells, whereas at high concentra-
tions patches were seen over the whole cell surface. Us-
ing green ﬂuorescent protein–tagged fragments of p85 
we show that binding to the receptor requires the NH
 
2
 
-
terminal part of the protein as well as its SH2 domains.
Key words: phosphatidylinositol 3-kinase • green ﬂu-
orescent protein • erbB-3 • focal complexes • tyrosine 
kinase
 
P
 
hosphatidylinositol
 
 3-kinase (PI 3-kinase)
 
1
 
 was
first identified as a lipid kinase activity associated
with the middle T antigen in polyoma virus (SV40)
transformed cells (Cantley et al., 1991). The enzyme phos-
phorylates inositol phospholipids at the D-3 position of
the inositol ring. Phosphatidylinositol 3-phosphate (PI-3-P)
is constitutively synthesized, whereas the other products of
PI 3-kinase, PI-3,4-P
 
2
 
 and PI-3,4,5-P
 
3
 
, are rapidly pro-
duced after growth factor stimulation (Auger et al., 1989),
and function directly as second messengers. PI 3-kinase is
known to be involved in a number of biological processes,
such as mitogenesis, protein trafficking, inhibition of apop-
tosis, and the regulation of actin and integrin functions
(Carpenter and Cantley, 1996). The enzyme is now known
to associate with several growth factor receptors, including
the erbB-3 receptor (Prigent and Gullick, 1994), platelet-
derived growth factor receptor (Klippel et al., 1992), hepa-
tocyte growth factor receptor (Ponzetto et al., 1993), NGF
receptor (Ohmichi et al., 1992), and insulin receptor via in-
sulin receptor substrate 1 (IRS-1) (Backer et al., 1992). It
also binds to nonreceptor tyrosine kinases such as mem-
bers of the src kinase family, and to the crk and abl onco-
gene products (Cantley et al., 1991). PI 3-kinase is a het-
erodimer consisting of an 85-kD regulatory subunit (p85)
and a 110-kD catalytic subunit (p110) (Otsu et al., 1991).
The p85 subunit contains several domains that mediate
protein–protein interactions. It has one NH
 
2
 
-terminal SH3
domain which binds to proline-rich sequences and two
SH2 domains which bind to the specific phosphotyrosine-
containing motif pYXXM. It also contains a region that is
homologous to the COOH-terminal portion of the break
cluster region gene product, which is flanked on either side
by proline-rich sequences (Kapeller and Cantley, 1994).
The p110 catalytic subunit is similar to the 
 
Saccharomy-
ces cerevisiae
 
 protein, VPS34, which is essential for pro-
tein sorting (Herman and Emr, 1990). VPS34 only uses
phosphatidylinositol as a substrate to produce phosphati-
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dylinositol 3-phosphate (PI-3-P) (Stack and Emr, 1994),
suggesting that the constitutive production of this phos-
pholipid in mammalian cells might be involved in pro-
tein trafficking. There are four known isoforms of p110,
termed 
 
a
 
, 
 
b
 
, 
 
d
 
, and 
 
g
 
 (Chantry et al., 1997; Ho et al., 1997).
The NH
 
2
 
-terminal region of p110
 
a
 
, 
 
b
 
, and 
 
d
 
 binds to p85
in the sequence that separates the SH2 domains, whereas
p110
 
g
 
 does not bind to p85 but its activity is stimulated by
G proteins (Stoyanov et al., 1995).
The downstream signaling events stimulated by the ac-
tion of PI 3-kinase are poorly understood. Known targets
of PI 3-kinase’s lipid products are protein kinase B (PKB),
also known as Akt and phosphoinositide-dependent pro-
tein kinase; phosphoinositide-dependent kinase 1 (PDK-
1), which is involved in the inhibition of apoptosis (Hem-
mings, 1997; Anderson et al., 1998); certain isoforms of
PKC (Nakanishi et al., 1993; Toker et al., 1994); and p70
 
S6
 
kinase (Weng et al., 1995). PI 3-kinase has also been de-
scribed as an upstream regulator of Rac and Rho in medi-
ating focal adhesion complexes, and stress fiber and lamel-
lipodia formation (Reif et al., 1996), and may also be
upstream of Ras signaling (Jhun et al., 1994; Hu et al.,
1995).
Although PI 3-kinase is thought to be involved in the
signaling pathways of a number of growth factor receptors
(Kapeller and Cantley, 1994), immunoprecipitation exper-
iments have shown that only a small fraction of the cyto-
plasmic pool of p85 is redistributed to the membrane after
ligand stimulation (Soler et al., 1994). Receptor signaling
might therefore result in the relocation of p85 to other lo-
cations, reflecting its diverse role in cellular functioning.
To investigate the distribution and movement of p85 in
live cells after ligand stimulation we have tagged the NH
 
2
 
terminus of human p85
 
a
 
 with green fluorescent protein
(GFP).
 
Materials and Methods
 
All chemicals were obtained from Sigma Chemical Co. unless otherwise
stated. The antibodies U1, U13, and U14 were obtained from Ivan Gout
(Ludwig Institute, London, United Kingdom). The antibody to the
COOH terminus of p85 was obtained from Transduction Laboratories,
and the antibody to p110 was obtained from Autogen Bioclear. The Sto
x22 antibody to clathrin was a kind gift of Julian Downward (Imperial
Cancer Research Fund, London, United Kingdom).
 
Cloning and Expression of GFP Fusion Proteins
 
p85 DNA was obtained from a human cDNA clone by PCR and then
fused to the COOH terminus of MUT2 GFP cDNA (gift of Stanley
Falkow, Stanford University, Stanford, CA; Cormack et al., 1996). GFP-
p85 contained all the 724 amino acids of the human p85
 
a
 
, GFP-2SH2 con-
tained amino acids 321–724, GFP-CSH2 contained amino acids 615–724,
and GFP-NSH2 contained amino acids 321–474. The chimeric cDNAs
were cloned into the CMV promoter-driven plasmid pcDNA3.1/Zeo (In-
vitrogen), and microinjected at 0.1 ng/nl into the nuclei of C18 cells which
had been serum starved (DMEM supplemented with 0.5% FCS) for 18 h.
 
Cell Culture and Transient Transfections
 
C18 (NIH-3T3 based), Cos-7, A431, and MCF-7 cells were cultured in
DMEM supplemented with 10% FCS. For transfection, 5 
 
3 
 
10
 
6
 
 Cos-7
cells were electroporated (0.3 kV, 250 
 
m
 
F, 0.4 mm cuvette) with 10 
 
m
 
g of
either the GFP-p85, GFP-2SH2, or pcDNA3.1/Zeo as a control. After 48 h,
the cells were lysed at 4
 
8
 
C in Triton buffer (50 mM Tris, pH 7.4, 5 mM
EGTA, 1% Triton X-100, 150 mM sodium chloride, 25 mM benzamidine,
 
10 
 
m
 
g/ml leupeptin, 0.2 mM sodium orthovanadate, 50 mM sodium fluo-
ride, 1 mM PMSF) for immunoprecipitation.
 
Protein Immunoprecipitations and Immunoblotting
 
The fusion proteins were in vitro transcribed and translated using a TNT-
coupled reticulocyte lysate system (Promega) with [
 
35
 
S]methionine label-
ing. The protein sizes were deduced using SDS-gel electrophoresis (10%
gel) and autoradiography. A 50-
 
m
 
l TNT reaction was sufficient for six im-
munoprecipitations. The reaction was diluted in 2.5 ml of PBS, and 400 
 
m
 
l
of the protein mix was immunoprecipitated for 2 h with antibodies bound
to protein A–Sepharose. The immunocomplexes were washed four times
with RIPA buffer (PBS with 1% Triton X-100, 0.1% SDS) and once with
PBS/0.2% Triton X-100 before being eluted with SDS-PAGE buffer at
high temperature.
GFP-p85 and GFP-2SH2 proteins from transiently transfected Cos-7
cells were immunoprecipitated using an antibody to GFP (gift of Dave
Shima, Imperial Cancer Research Fund, London) to distinguish them
from the endogenous p85. Proteins were separated on a 10% SDS-poly-
acrylamide gel and subjected to Western blotting with an antibody to p85
(1:250; Transduction Laboratories). The filter was then stripped for 1 h at
60
 
8
 
C with 2% SDS, 100 mM mercaptoethanol in 62.5 mM Tris, pH 6.8.
This was then blocked and reprobed with an antibody to the p110 catalytic
subunit (1 
 
m
 
g/ml; Autogen Bioclear). Detection was by incubation with
horseradish peroxidase–conjugated secondary antibody and visualization
was by enhanced chemiluminescence (Amersham).
C18 cells in 9-cm dishes (80% confluent) were stimulated with 5 
 
3 
 
10
 
2
 
7 
 
M
EGF for 2.5 min to bring about phosphorylation of the erbB-3 chimera.
The cells were lysed in Triton X-100 buffer at 4
 
8
 
C. The chimera was pre-
cipitated for 2 h with 5 
 
m
 
g of EGF receptor 1 (EGFR1) which reacts with
the extracellular domain of EGFR and 2.5 mg of protein A–Sepharose.
Immunocomplexes were washed and analyzed as above. The phosphory-
lation status of the chimera was assessed using an antibody specific for
phosphotyrosine (PY20, 1:1,000; Transduction Laboratories).
 
Fluorescence Imaging and Immunofluorescence
 
Microscopy was performed using a Zeiss Axiovert 135 microscope using a
63
 
3
 
 objective lens with fluorescein and Cy3 filters. The images were cap-
tured with a CCD camera and processed using IPLab and Photoshop 4.0
software. Fluorescence intensity was normalized to the first time point in
the films. The temperature was maintained throughout at 37
 
8
 
C using an
environmental chamber.
For immunofluorescence, cells were grown on glass coverslips. They
were fixed at 4
 
8
 
C for 15 min with 4% paraformaldehyde, permeabilized
with 0.5% Triton X-100 in PBS, and incubated with 1:50 antivinculin anti-
body (Sigma Chemical Co.). Antibody detection was by reaction with
Cy3-conjugated goat anti–mouse IgG for 20 min at room temperature. Lo-
calization of clathrin was performed essentially as for vinculin using the
anticlathrin mouse mAb Sto x22 at 1:100. Immunostaining for the chimera
was performed using the EGFR1 mAb as described by Gullick et al.
(1985).
 
Results
 
Construction of GFP-p85 Fusion Proteins
 
A number of constructs were made containing different
portions of p85 fused to GFP: the full length p85 protein
(GFP-p85), the two SH2 domains (GFP-2SH2), the NH
 
2
 
-
terminal SH2 domain (GFP-NSH2), and COOH-terminal
SH2 domain (GFP-CSH2). The constructs were in vitro
transcribed and translated in the presence of [
 
35
 
S]methio-
nine, and the resulting proteins were immunoprecipitated
with antibodies to GFP and p85 to check the integrity of
the encoded proteins (Fig. 1). GFP-p85 was immunopre-
cipitated with an antibody to GFP, the inter–NSH2-SH3
domain (U1), the SH3 domain (U13), and the COOH-ter-
minal SH2 domain (Transduction Laboratories) (Fig. 1 A,
lanes 1–4, respectively). GFP-2SH2 was immunoprecipi-
tated with antibodies to GFP and the NH
 
2
 
- (U14) and 
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COOH-terminal SH2 domains (Transduction Laborato-
ries) (Fig. 1 B, lanes 1–3, respectively). GFP-CSH2 and
GFP-NSH2 were immunoprecipitated with anti-GFP and
COOH- and NH
 
2
 
-terminal SH2 domain antibodies, re-
spectively (Fig. 1 B, lanes 5 and 6; Fig. 1 A, lanes 6 and 7).
GFP-p85 was able to bind weakly to protein A–Sepharose
in the absence of antibody (Fig. 1 A, lane 5), possibly due
to exposure of hydrophobic sequences in the unfolded
protein. The COOH-terminal SH2 antibody immunopre-
cipitated GFP-p85 and GFP-2SH2 well but GFP-CSH2
very weakly, which suggests that the antibody recognizes
the larger protein with a higher affinity.
p85 binds the p110 catalytic subunit between its two
SH2 domains to form the holoenzyme. To determine
whether the GFP-tagged proteins engineered to encode
this region retained their ability to bind p110, the full
length and the 2SH2 constructs were transiently trans-
fected into Cos-7 cells. The expressed proteins were im-
munoprecipitated with an antibody to GFP to distinguish
them from the endogenous p85 and were then analyzed by
SDS-PAGE and immunoblotting. The proteins were blot-
ted with an antibody against p85 (Fig. 1 C, lanes 2 and 3)
and then reprobed with an antibody to p110 (Fig. 1 D,
lanes 2 and 3). In both the full length and 2SH2 transfected
cells, but not the mock transfected cells (Fig. 1, C and D,
lane 1), the p110 subunit was coimmunoprecipitated, indi-
cating that the addition of GFP to their NH
 
2
 
 termini did
not interfere with their ability to form heterodimers.
 
Expression and Visualization of GFP Fusion 
Constructs in Live Cells
 
The behavior of the GFP-p85 proteins in live cells was as-
sessed by digital fluorescence microscopy. A stable NIH-
3T3 cell line (C18) was used which expressed low levels of
endogenous murine EGFRs (
 
,
 
2,000/cell) and a high level
of a chimera of the extracellular domain of human EGFR
fused to the cytoplasmic domain of human c-erbB-3
(130,000/cell) (Prigent and Gullick, 1994). Activation with
EGF has been shown previously to recruit p85 to the chi-
mera (Prigent and Gullick, 1994; Soltoff et al., 1994), prob-
ably as a result of transphosphorylation by endogenous
EGFRs because the erbB-3 receptor is thought to be ki-
nase defective (Sierke et al., 1997). Intranuclear microin-
jection of the C18 cells with the GFP-p85 construct re-
sulted in visible expression as early as 2 h after injection.
The protein was distributed throughout the cytoplasm and
was excluded from the nucleus (Fig. 2 A). The GFP-
tagged 2SH2, CSH2, and the NSH2 domains were distrib-
uted throughout the cytoplasm but were also present to a
lesser extent in the nucleus (Fig. 2, B, C, and D, respec-
tively).
The GFP-p85 and GFP-2SH2 proteins, but not the
smaller constructs, were also localized at discrete points at
the periphery of the cell (Fig. 3 A), which were identified
as focal complexes by colocalization experiments with an
antibody to vinculin (Fig. 3, B and C), demonstrating that
both of the SH2 domains have to be present for this local-
ization to occur. This peripheral localization of p85 was
also apparent in the epithelial cell lines, A431 and MCF-7,
after microinjection with GFP-p85 (Fig. 2, E and F, respec-
tively).
 
EGF Stimulation of GFP-p85–expressing Cells
 
Addition of 500 nM EGF to C18 cells expressing the GFP-
p85 protein resulted in recruitment of p85 to the cell sur-
face where it formed patches (Fig. 4 and Quicktime movie
at http://www.lif.icnet.uk/axp/rbl/index.html). The EGFR/
c-erbB-3 chimera was also visualized after 500 nM EGF
addition using an anti-EGFR antibody. Fig. 5, A and B,
shows that the receptors cluster to form the same patching
pattern. To confirm that p85 is localizing to the receptor
and not to another cellular site, rhodamine EGF was used
Figure 1. Characterization of the
GFP-p85 fusion constructs. The
cDNA constructs were in vitro
translated using [35S]methionine.
GFP-p85 was immunoprecipi-
tated with an antibody to GFP,
the inter–NSH2-SH3 domain
(U1), the SH3 domain (U13),
the COOH-terminal SH2 domain
(Transduction Laboratories), and
with protein A–Sepharose alone
(A, lanes 1–5, respectively).
GFP-2SH2 was immunoprecipi-
tated with antibodies to GFP,
the NH2 (U14) and COOH ter-
mini, (Transduction Laboratories),
and protein A–Sepharose alone
(B, lanes 1–4, respectively). GFP-
CSH2 and GFP-NSH2 were im-
munoprecipitated with anti-GFP,
COOH- and NH2-terminal anti-
bodies, respectively, and with a
protein A–Sepharose control (B, lanes 5–7; A, lanes 6–8). To assess whether GFP-p85 bound to the p110 catalytic subunit, Cos-7 cells
were transiently transfected with the GFP-p85, GFP-2SH2, and pcDNA3.1/Zeo constructs (Mock, C and D). The cells were lysed and
immunoprecipitated with an antibody to GFP, transferred to nitrocellulose, probed with an antibody to p85 (C), and stripped and re-
probed with an antibody to the p110 catalytic subunit of PI 3-kinase (D). 
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to mark the external part of the receptor. Incubation of in-
jected cells with 50 nM rhodamine EGF for 5 min resulted
in patching indistinguishable from unlabeled ligand. Paired
rhodamine/GFP images of the cells were then taken. A
similar pattern was obtained for the rhodamine and GFP
images, demonstrating that the majority of p85 relocalizes
to the receptor (Fig. 5, C–E). Expression of the GFP-p85
protein in mock-transfected NIH-3T3 cells also resulted in
focal complex localization in unstimulated and stimulated
cells, but no patching was seen after EGF addition, indi-
cating that p85 was only recruited to the erbB-3 chimera
and not to endogenous EGFR homodimers (data not
shown).
Recruitment to the receptor was first visible after 30 s
and was observed up to 1 h after EGF addition. During
this time no visible internalization occurred. Cells were
costained with anticlathrin antibodies to demonstrate the
lack of coated vesicles or early endosomes associated with
the patches (Fig. 5, F–H). There was also no change over
1 h after ligand stimulation in the localization of the
tagged PI 3-kinase at the focal complex sites.
EGF addition to A431 cells expressing the GFP-p85
protein also resulted in translocation to the membrane and
patching (Fig. 6 A). In A431 cells, the EGFR is normally
present at the base of microvilli. Immediately after 500 nM
EGF addition, the surface of the cells and the microvilli
undergo ruffling, hence GFP-p85 recruitment to the recep-
tor at the base of the microvilli is visible as a wave pattern.
After 10 min, when the ruffling has subsided, the familiar
patching pattern was observed. The patches are roughly
the same size as those formed in C18 cells, which is to be
expected as they have similar levels of erbB-3 present
(Soltoff et al., 1994). Although internalization was not
generally apparent in this cell line, certain individual cells
showed signs of internalization after 1 h of EGF incuba-
tion (Fig. 6 B).
Visualization of the clustering of the p85–receptor com-
plex also enabled us to identify changes in cluster forma-
tion in response to ligand concentration. At 500 and 50 nM
EGF, clustering occurs in patches over the complete sur-
face of the C18 cells within 2–3 min. At 5 nM EGF, how-
ever, the clustering occurred reproducibly at the cells’ pe-
riphery (Fig. 7, and see also the Quicktime movie at http://
www.lif.icnet.uk/axp/rbl/index.html). At the lower EGF
Figure 2. Localization of
GFP-p85 and its subfrag-
ments in serum-starved cells,
not exposed to an activating
ligand. The constructs were
microinjected into the nuclei
of the cells, and the distribu-
tion of the proteins was visu-
alized using fluorescence mi-
croscopy after 2–5 h. The
typical appearance of C18
cells expressing GFP-p85 (A),
GFP-2SH2 (B), GFP-CSH2
(C), and GFP-NSH2 (D). (E)
The typical appearance of
unstimulated A431 cells and
(F) MCF-7 cells expressing
the GFP-p85 protein. 
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concentration of 0.5 nM and 50 pM no patches were ob-
served (Fig. 8).
 
Characterization of the Requirements for
Translocation of p85
 
The mechanism by which p85 translocates to the mem-
brane after activation is not known. Relocation of p85
could be by diffusion or could be regulated by its lipid
products (Janmey, 1995) or by interaction with the actin
cytoskeleton (Fincham et al., 1996). PI 3-kinase activity
has been suggested to be involved in actin cytoskeleton–
dependent translocation of src to the cell membrane be-
cause of its affinity for v-src and also because of its role in
protein trafficking (Brown et al., 1995; Joly et al., 1995).
To address whether p85 redistribution is controlled in a
similar manner, cells expressing GFP-p85 were incubated
with cytochalasin D to disrupt the actin cytoskeleton (Fig.
Figure 3. Colocalization of
GFP-p85 with vinculin at
focal adhesion complexes.
Cells were stimulated with
EGF for 5 min then fixed in
4% paraformaldehyde. A
GFP image was taken of the
cell (A). Vinculin was de-
tected using a mouse antivin-
culin antibody and a Cy3-
labeled rabbit anti–mouse
secondary antibody (B). (C)
Merge of the two images
showing colocalization.
Figure 4. Relocalization of
GFP-p85 in response to
ligand activation in C18 cells.
Distribution of GFP-p85 ev-
ery 20 s after 500 nM EGF
addition (for Quicktime movie,
see http://www.lif.icnet.uk/axp/
rbl/index.html). 
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Figure 5. Characterization of the EGF-induced patches. C18 cells were incubated for 5 min with 500 nM EGF and then fixed and
stained with an anti-EGFR antibody and a FITC-conjugated secondary antibody. The position of the receptor is therefore visible before
(A) and after (B) EGF addition. C18 cells expressing GFP-p85 were incubated with 50 nM rhodamine-labeled EGF for 5 min to again
mark the position of the receptor. A GFP (C) and rhodamine image (D) was taken of the same cell. This was then merged to show the
colocalization of the two images (E). C18 cells expressing GFP-p85 were stimulated with 500 nM EGF for 5 min, fixed and stained with
anti-clathrin antibodies. (F) GFP image, (G) clathrin image, and (H) merged image showing no colocalization. 
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Figure 6. Relocalization of
GFP-p85 in response to
ligand activation in A431
cells. (A) A431 cells were
treated with 500 nM EGF
and pictures were taken of
the same cells over a period
of 1 h. (B) Another cell from
the same plate of cells.
Figure 7. Relocalization of
GFP-p85 in response to a low
ligand concentration in C18
cells. Distribution of GFP-p85
every 20 s after the addition
of 5 nM EGF (for Quicktime
movie, see http://www.lif.
icnet.uk/axp/rbl/index.html). 
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9 D). Although cytochalasin D is not thought to depoly-
merize all cellular actin, phalloidin staining of the treated
cells showed that most was disrupted and the cell shape
was visibly distorted. Despite this treatment, p85 was still
able to translocate to the membrane after EGF addition
(Fig. 9 B). Treatment of GFP-p85–expressing cells with
Ly294002, an inhibitor of PI 3-kinase activity, also did not
affect p85 movement (Fig. 9 F). These data suggest that
p85 translocation to the membrane is not dependent on
the catalytic activity of the enzyme or the integrity of the
actin cytoskeleton. However, relocalization was inhibited
by the EGFR tyrosine kinase inhibitor AG1478 (Fig. 10
A) at a concentration (1 
 
m
 
M) sufficient to completely in-
hibit receptor tyrosine phosphorylation (Fig. 10 B), dem-
onstrating that this activity is required. Thus, although
SH2 binding is required it does not appear to be sufficient
for relocalization since EGF addition to cells expressing
either the two SH2 domains or the NH
 
2
 
- or COOH-termi-
nal SH2 domain alone did not result in patching (data not
shown).
 
Discussion
 
Direct visualization of p85 within live cells results in posi-
tional information about the signaling molecule that can-
not be easily obtained by traditional biochemical methods.
We have observed a focal complex localization for PI 3-kinase
in resting cells, which is dependent on the binding of the
Figure 8. Effect of ligand
concentration on GFP-p85
distribution. The distribu-
tion of GFP-p85 in C18 cells
5 min after the addition of 50
nM EGF (A), 5 nM EGF
(B), 0.5 nM EGF (C), and 50
pM EGF (D). 
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two SH2 domains of p85. Focal adhesions not only act as
structural links between the extracellular matrix and the
actin cytoskeleton but also transduce biochemical signals
from the extracellular matrix (Burridge et al., 1988). Clus-
tering of cell surface integrins is associated with the ty-
rosine phosphorylation of a number of focal adhesion pro-
teins. In fibroblasts these include focal adhesion kinase,
tensin, p130
 
cas
 
, and paxillin (Burridge et al., 1992; Bock-
holt and Burridge, 1993; Clark and Brugge, 1995; Vuori et
al., 1996). These proteins can then interact with signaling
molecules which contain SH2 domains, such as src kinases
(Vuori et al., 1996), csk, and adapter proteins, such as crk
and Grb2 (Bergman et al., 1995; Nakamoto et al., 1996;
Schlaepfer et al., 1994). p85 association with focal adhe-
sion kinases via its SH2 domains in vitro has been de-
scribed previously (Chen and Guan, 1994). p120
 
cbl
 
, an
adapter protein, has also been reported to bind PI 3-kinase
in macrophages and in PC12 cells. In PC12 cells, p120
 
cbl
 
was thought to link PI 3-kinase to the EGFR indepen-
dently of the presence of erbB-3 (Soltoff and Cantley,
1996). However, we did not see any evidence of EGFR/PI
3-kinase linkage in NIH-3T3 cells without chimera after
EGF stimulation (data not shown), although this may be
due to very low levels of EGFR expression. In macro-
phages, p120
 
cbl
 
 has been reported to link PI 3-kinase to the
integrin signaling pathway (Ojaniemi et al., 1997). Both fo-
cal adhesion kinase and p120
 
cbl
 
 are potential p85 binding
sites because they both have at least two pYXXM motifs
(Soltoff et al., 1994; Chen and Guan, 1994). Association of
PI 3-kinase with other focal adhesion proteins such as src
kinase has been described, but these interactions are medi-
ated via SH3 domains and cannot be responsible for the
binding seen during these experiments (Liu et al., 1993;
Pleiman et al., 1994).
It is interesting that PI 3-kinase is only associated with
focal complexes at the periphery of the cells, and not to fo-
cal adhesions underneath the cell. Focal complexes share
many constituents with focal adhesions but they are mor-
phologically distinct (Hall, 1998). PI 3-kinase at these
complexes may be involved in the signal pathways that are
responsible for membrane ruffling and cell migration, es-
pecially since it is known to be involved in hepatocyte
growth factor–induced cell scattering of MDCK cells
(Royal and Park, 1995; Royal et al., 1997). Such focal com-
plexes are under the control of Rac, which has been identi-
fied as a downstream target of PI 3-kinase (Reif et al.,
1996). The focal complex localization of p85 indicates that
PI 3-kinase is directly involved in signaling through these
complexes and not just as an upstream regulator.
After 500 nM EGF stimulation, GFP-p85 is rapidly
translocated to the EGFR/erbB-3 receptor dimers which
then form patches. No other cellular relocation was ob-
served. In C18 cells, the patches appear to remain at the
cell membrane with no obvious receptor internalization
occurring. The patches were also not associated with clath-
rin, which suggests that the receptors were not being inter-
nalized into endosomal vesicles. Heregulin is slowly inter-
nalized and degraded when it is added to cells that express
high levels of erbB-3 and erbB-2 receptors (Baulida and
Carpenter, 1997). Experiments using a similar EGFR/
erbB-3 chimera in NIH-3T3 cells have also shown that in-
ternalization is very limited and the half-life of the recep-
tor remains unchanged after the addition of EGF (Baulida
et al., 1996). EGFR is the only member of the type 1
growth factor receptor family that can internalize nor-
mally (Baulida et al., 1996), and in A431 cells certain indi-
vidual cells did show signs of receptor/p85 internalization.
The difference in receptor trafficking between the cell
lines could be due to their receptor status. C18 cells have
60 times more (chimeric) erbB-3 receptor than EGFR.
Figure 9. The effect of specific inhibitors on GFP-p85 relocation
in response to 500 nM EGF. Cells were treated for 1 h with 0.1
mg/ml cytochalasin D, and the GFP-p85 was visualized before
(A) and after (B) a 5-min incubation with 500 nM EGF. The ap-
pearance of the actin cytoskeleton was visualized with Cy3-
labeled phalloidin in untreated serum-starved C18 cells (C) and
in serum-starved cells treated with 0.1 mg/ml cytochalasin D for
1 h (D). The PI 3-kinase inhibitor Ly294002 was added to C18 cells
at 10 mM for 15 min, and the GFP-p85 was visualized before ligand
addition (E) and 5 min after the addition of 500 nM EGF (F). 
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Upon EGF stimulation the predominant receptor present
in the receptor/GFP-p85 clusters will be erbB-3, which
slows down the dimer internalization. In A431 cells, there
is 10 times more EGFR present than erbB-3. After EGF
stimulation of these cells, the predominant receptor in the
clusters will be EGFR, which might explain why internal-
ization appears to occur after 1 h of ligand stimulation.
Note that this is slower than expected for EGFR ex-
pressed alone, but as PI 3-kinase binds only to erbB-3, we
are presumably only following internalization of erbB-3/
EGFR heterodimers.
p85 remains visible in the clusters at the cell membrane
for up to 1 h. After 45 min, the erbB-3 chimera is fully de-
phosphorylated and mitogenic signaling should be attenu-
ated (Prigent and Gullick, 1994). PI 3-kinase has been im-
plicated in the trafficking of receptors in mammalian cells;
indeed, the presence of p85 binding sites on the platelet-
derived growth factor receptor is required for its traffick-
ing and degradation (Joly et al., 1995), and p85 has been
reported to be internalized with the receptor (Kapeller et
al., 1993). Wortmannin, a PI 3-kinase inhibitor (Okada et
al., 1994), can also affect other processes, such as trans-
ferrin receptor recycling (Martys et al., 1996) and transcy-
tosis (Hansen et al., 1995). It can also induce changes in
the morphology of endosomes (Shpetner et al., 1996). PI
3-kinase lies upstream of early endosomal antigen 1, which
binds to endosomes (Patki et al., 1997), and upstream of
Rab5, which regulates early endosome fusion (Li et al.,
1995). These data suggest that a continuous p85 presence
may be involved in the trafficking of the erbB-3 receptor,
which is probably recycled rather than degraded (Water-
man et al., 1998).
The translocation of p85 to the receptor is not depen-
dent on PI 3-kinase activity or the actin cytoskeleton; thus,
its binding to erbB-3 is more likely due to random collision
rather than active relocation. However, it is dependent on
the tyrosine phosphorylation of the cytoplasmic domain of
erbB-3, which allows SH2 interactions. It is generally be-
lieved that the two SH2 domains are all that are required
for receptor binding (McGlade et al., 1992). However, the
results presented here suggest that the NH
 
2
 
-terminal por-
tion of the protein (containing the SH3, Bcr, and proline-
rich domains) is also important in localizing p85 to the
erbB-3 receptor, possibly due to self association allowing
the recruitment of additional copies to the complex, or by
stabilization of p85 at the receptor by binding to other sig-
naling molecules.
PI 3-kinase itself has many functions in different intra-
cellular systems. Our results demonstrate that in NIH-3T3
cells it exists at focal complexes and probably as an inac-
tive cytoplasmic pool which is drawn to the cell surface by
growth factor receptors in response to extracellular sig-
nals. Direct visualization of the subcellular location of sec-
ond messengers using this technique will allow similar ex-
periments in other cell types and in response to other
stimuli to determine if these are common effects. In these
environments, low affinity interactions, possibly not mea-
surable by biochemical techniques, may be observed with
activators, substrates, and downstream molecules. Finally,
since ligand binding does not accelerate internalization of
c-erbB-3 (or c-erbB-2 and c-erbB-4), it is not clear why re-
ceptor clustering occurs in this system. It is also not known
if ligand-unoccupied as well as occupied receptors are
present in these patches. It is possible that such behavior
may control signal sensitivity by mechanisms such as those
described recently by Bray et al. (1998). It is also possible
Figure 10. Inhibition of EGF-
induced chimera autophos-
phorylation and GFP-p85
translocation by tyrphostin
AG-1478. (A) C18 cells were
treated for 30 min with 1 mM
AG-1478, and the GFP-p85
was visualized before and 5
min after the addition of 500
nM EGF. (B) The effect of
AG-1478 on chimera phos-
phorylation was assessed by
incubating cells with varying
concentrations of inhibitor
followed by cell stimulation
with 500 nM EGF for 2.5
min. The chimera was immu-
noprecipitated with an mAb
to the extracellular domain,
transferred to nitrocellulose,
and Western blotted with an
antibody against phosphoty-
rosine (PY20). 
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that aggregation of second messenger molecules or the
juxtaposition of different second messengers may permit
combinatorial signaling. Light-based systems should be
helpful in exploring such models. Moreover, they might be
utilized to act as screens for promising pharmacological
activators or inhibitors.
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